Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 7, Issue 9, Pages 508-519Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.116
Keywords
-
Categories
Funding
- Breakthrough Breast Cancer
- Cancer Research UK
Ask authors/readers for more resources
Drugs that inhibit the enzyme poly(ADP-ribose) polymerase (PARP) are showing considerable promise for the treatment of cancers that have mutations in the BRCA1 or BRCA2 tumor suppressors. This therapeutic approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in these tumors. High-grade ovarian cancers have a generally poor prognosis, and accumulating evidence suggests that mutations in BRCA1 or BRCA2, or silencing of BRCA1 by promoter methylation, may be common in this disease. Here, we consider how the potential benefit of PARP inhibitors might be maximized in ovarian cancer. We suggest that it will be crucial to explore novel therapeutic trial strategies and drug combinations, and incorporate robust biomarkers predictive of response if these drugs are to reach their full potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available